Investigating the role of mGluR5 signaling in schizophrenia
mGluR5 hypoactivity is integral to glutamatergic dysregulation in schizophrenia
This study is looking at how a certain brain receptor, mGluR5, works differently in people with schizophrenia, hoping to find out why it doesn't function as it should and how that might relate to the symptoms of the condition, which could help in developing better treatments in the future.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10766120 on NIH RePORTER |
What this research studies
This research focuses on understanding how the signaling of a specific receptor, mGluR5, is altered in individuals with schizophrenia. By examining brain tissue from patients, the study aims to identify the mechanisms behind reduced mGluR5 activity and its impact on other signaling pathways related to schizophrenia. The researchers will analyze the interactions between mGluR5 and NMDA receptors to uncover potential dysregulations that contribute to the symptoms of the disorder. This work could lead to new insights into the biological underpinnings of schizophrenia and inform future treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with schizophrenia who may be experiencing symptoms related to glutamatergic dysregulation.
Not a fit: Patients with schizophrenia who do not exhibit mGluR5 signaling alterations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with schizophrenia by targeting the underlying signaling pathways.
How similar studies have performed: Previous research has shown promising results in understanding receptor signaling in schizophrenia, suggesting that this approach may yield valuable insights.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Hahn, Chang-Gyu — Thomas Jefferson University
- Study coordinator: Hahn, Chang-Gyu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.